Search
News
Research Grants Bring More Than $29 Million Supporting Work of Roswell Park Scientists
… received $420,500 toward the clinical study led by Pawel Kalinski, MD, PhD, and Brahm Segal, MD, of a two-drug … immunotherapy combination as treatment for COVID-19. Dr. Kalinski has led pioneering studies proposing that …
Pancreatic Cancer Research Center
… X, Chakraborty S, Fountzilas C, Wang J, Jamroze A, Liu X, Kalinski P, Tang DG. Role of the DEAD-box RNA helicase DDX5 … PMCID: PMC9925045. 2022 Zhu Z, McGray AJR, Jiang W, Lu B, Kalinski P, Guo ZS. Improving cancer immunotherapy by …
Page with Layout
Wei Lab Publications
… LT, Dong B, Cortes Gomez E, Wei L, Witkiewicz AK, Yao S, Kalinski P, Singh AK. Concurrent Aspirin Use Is Associated … LT, Dong B, Cortes Gomez E, Wei L, Witkiewicz AK, Yao S, Kalinski P, Singh AK. Concurrent Aspirin Use Is Associated …
Blog Post
Cancer Innovations: Making immunotherapy work for more patients
… of the most commonly prescribed immunotherapies,” says Dr. Kalinski. Other clinical trials at Roswell Park involve … of the most commonly prescribed immunotherapies,” says Dr. Kalinski. Other clinical trials at Roswell Park involve …
News
Roswell Park Clinical Trial Points Toward Promising New Therapy for Most Aggressive Type of Breast Cancer
… increases the risk of immune-related adverse events. Pawel Kalinski, MD, PhD , Professor of Immunology at Roswell Park, … increases the risk of immune-related adverse events. Pawel Kalinski, MD, PhD , Professor of Immunology at Roswell Park, …
Tumor Immunology & Immunotherapy Research Program
… Minderman H, Maguire O, O'Connor TL, Early AP, Levine EG, Kalinski P. Systemic infusion of TLR3-ligand and IFN-α in … SG, Sexton S, Sait SJ, Singh PK, Wang J, Maitra A, Kalinski P, DePinho RA, Wang H, Liao W, Abrams SI, Segal BH, …
Advanced Tissue Imaging Shared Resource (ATISR)
… Minderman H, Maguire O, O'Connor TL, Early AP, Levine EG, Kalinski P. Systemic infusion of TLR3-ligand and IFN-α in … SI, Wang C, Hutson AD, Attwood K, Hicks KA, Jurcevic JA, Kalinski P, Iyer R, Boland PM. Phase Ib/II Study of Cetuximab …
News
Roswell Park Takes in New Research Funding Totaling Nearly $22 Million
… a multimillion-dollar Breakthrough Award to Pawel Kalinski, MD, PhD, to assess a three-pronged immunotherapy … a multimillion-dollar Breakthrough Award to Pawel Kalinski, MD, PhD, to assess a three-pronged immunotherapy …
Comparative Oncology Shared Resource (COSR)
… SG, Sexton S, Sait SJ, Singh PK, Wang J, Maitra A, Kalinski P, DePinho RA, Wang H, Liao W, Abrams SI, Segal BH, …